These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 614548)

  • 21. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hypotensive effect of delayed-action oxprenolol and chlorthalidone in combined form in patients with primary arterial hypertension].
    Cybulska I; Sznajderman M
    Pol Tyg Lek; 1984 Apr; 39(15):501-3. PubMed ID: 6384962
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect on HDL cholesterol of oxprenolol and atenolol.
    Kjeldsen SE; Eide I; Leren P; Foss OP; Holme I; Eriksen IL
    Scand J Clin Lab Invest; 1982 Sep; 42(5):449-53. PubMed ID: 6130595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of nitroglycerin on exercise hemodynamics in patients with coronary heart disease under treatment with beta-blockers (mepindolol, oxprenolol) and a calcium-antagonist (fendiline) (author's transl)].
    Reiterer W
    Wien Med Wochenschr; 1980 Dec; 130(23):772-7. PubMed ID: 6111161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Essential arterial hypertension. Antihypertensive effect of the beta adrenergic blockader pindolol].
    Torres Zamora M
    Prensa Med Mex; 1977; 42(3-4):127-32. PubMed ID: 917991
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advantages of a fixed association of oxprenolol-chlorthalidone, as opposed to chlorthalidone alone, in the treatment of chronic essential arterial hypertension].
    Baronchelli A; Agosta R; Verdecchia P; Bichisao E
    Clin Ter; 1981 Apr; 97(1):63-9. PubMed ID: 7026137
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of 3-month treatment with propranolol, oxprenolol, metoprolol and pindolol on plasma lipids and lipoproteins in patients with primary arterial hypertension].
    Sznajderman M; Cybulska I; Niegowska J; Zawadzki Z; Sznajderman M
    Kardiol Pol; 1985; 28(7):489-99. PubMed ID: 2868145
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effectiveness of trimetazidine in patients with hypertension and the symptoms of coronary disease].
    Kozakiewicz K; Petelenz T; Chruściel TL
    Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):594-6. PubMed ID: 1488335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the effects of propranolol, practolol, oxyprenolol and L.B. 46 on myocardial contractility].
    Adamska-Dyniewska H
    Wiad Lek; 1973 Apr; 26(7):603-8. PubMed ID: 4144788
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of oxprenolol on the dynamics of left ventricular contraction in patients with coronary disease].
    Hoszowski K; Prosińska-Kibler M
    Kardiol Pol; 1972; 15(4):433-6. PubMed ID: 4641913
    [No Abstract]   [Full Text] [Related]  

  • 31. Oxprenolol in hypertension.
    Marshall AJ; Barritt DW
    Br J Clin Pract; 1973 Sep; 27(9):337-40. PubMed ID: 4595073
    [No Abstract]   [Full Text] [Related]  

  • 32. [Combined evaluation of the therapeutic activity of nifedipine in coronary insufficiency alone and with hypertension].
    Di Marco G; De Simone G; Cionci M; Patriarchi F; Spadano E
    Boll Soc Ital Cardiol; 1980; 25(3):231-44. PubMed ID: 7284128
    [No Abstract]   [Full Text] [Related]  

  • 33. [Test with the use of the adrenergic beta receptor blockader trasicor in the differential diagnosis of arterial hypertension].
    Velikanov KA; Shvets VD
    Sov Med; 1983; (4):88-91. PubMed ID: 6135258
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy of excited psychoses using a beta receptor blockader (oxprenolol) in high dosage].
    Volk W; Bier W; Braun JP; Grüter W; Spiegelberg U
    Nervenarzt; 1972 Sep; 43(9):491-2. PubMed ID: 5076477
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardioprotection by beta-blockers: molecular and structural aspects in experimental hypertension.
    Pauletto P; Vescovo G; Scannapieco G; Pessina AC; Dal Palù C
    Drugs Exp Clin Res; 1990; 16(3):123-8. PubMed ID: 1974839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience in the ambulatory treatment of primary arterial hypertension with a fixed oxprenolol-chlorthalidone combination].
    Zampaglione G; Ferrari O; Bianchi C; Bonifazi C; Coppetti S; Costanza G; Lanzarini L; Ricevuti A; Rinaldo R; Rizzi GM; Tavecchi L; Ziletti G; Distante S
    G Clin Med; 1980 Oct; 61(10):776-88. PubMed ID: 7239053
    [No Abstract]   [Full Text] [Related]  

  • 37. Captopril and oxprenolol in a fixed combination with thiazide diuretics: comparison of their antihypertensive efficacy and metabolic effects.
    Costa FV; Borghi C; Ambrosioni E
    Clin Ther; 1984; 6(5):708-18. PubMed ID: 6383615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effects of beta-adrenergic blockade in coronary artery surgery: clinical research.
    Yorulmaz FM; Kuralay E; Tatar H; Süer H; Oztürk OY
    Cardiovasc Surg; 1993 Aug; 1(4):410-3. PubMed ID: 7915625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-hypertensive efficacy of combined alpha- and beta-adrenoreceptor blockade with phentolamine-oxprenolol or with labetalol (AH 5158).
    Johnson BF; LaBrooy J; Munro-Faure AD
    Clin Sci Mol Med Suppl; 1976 Dec; 3():505s-507s. PubMed ID: 799558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of antihypertensive drug treatment on the incidence of cardiovascular morbidity and mortality in mild arterial hypertension].
    Tomov I
    Vutr Boles; 1985; 24(6):39-47. PubMed ID: 3913145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.